Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1236 results
February 2019
-
Press Release
Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)
Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea… -
Press Release
Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver…
January 2019
-
Ad-hoc Releases
En 2018, Novartis a enregistré une forte croissance de ses ventes, avec une expansion de sa marge core, développé des plates-formes leaders de traitements de pointe, et recentré l'entreprise
Hausse du chiffre d'affaires net de 5% (tcc[1], +6% USD) en 2018, soutenue par l'excellente performance des moteurs de croissance: Pharmaceuticals: cette unité opérationnelle a progressé de 7% (… -
Ad-hoc Releases
Novartis erzielt 2018 ein kräftiges Umsatzwachstum bei gleichzeitiger Steigerung der Kerngewinnmarge, baut wegweisende Therapie¬plattformen auf und fokussiert das Unternehmen
Der Nettoumsatz steigt im Geschäftsjahr um 5% (kWk[1], +6% USD) dank starker Performance der Wachstumstreiber: Die Geschäftseinheit Pharmaceuticals wächst um 7% (kWk), getragen von Cosentyx mit… -
Ad-hoc Releases
Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018
Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0… -
Press Release
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are… -
Press Release
Sandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use Disorder
reSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a…
December 2018
-
Ad-hoc Releases
Novartis successfully completes acquisition of Endocyte
Adds 177Lu-PSMA-617, a potential first-in-class radioligand therapy in Phase III development for metastatic castration-resistant prostate cancer (mCRPC) Strengthens leadership in nuclear… -
Press Release
Novartis receives European Commission (EC) approval for expanded indication for Kisqali® (ribociclib)
Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali® (ribociclib), the CDK4/6 inhibitor with the largest body of… -
Press Release
Novartis announces offer to acquire CellforCure to expand manufacturing capacity for innovative cell and gene therapies
Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah® (tisagenlecleucel) and recent successful completion of… -
Ad-hoc Releases
Novartis announces new CEO of Oncology Business Unit
Susanne Schaffert, Ph.D., President, AAA, an established Novartis executive, named new CEO, Novartis Oncology Basel, December 20, 2018 - Novartis announced today that Susanne Schaffert, Ph.D.,… -
Press Release
Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises
Agreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart Over 400 million people worldwide have…